Prostate cancer research in India: A scientometric analysis of publications output during 2004-13

Brij Mohan Gupta, Ritu Gupta

1National Institute of Science, Technology & Development Studies (NISTADS), New Delhi 11012, India
2Shri Venkateshwar University, Meerut- 250 002, India

Received November 16, 2014; Revised January 16, 2015; Accepted January 20, 2015; Published Online January 22, 2015

Review Article

Abstract

This review article examines 1,368 publications on prostate cancer in India, as covered in Scopus database during 2004-13, experiencing an annual average growth rate of 18.77% and citation impact of 5.23. The world prostate cancer output (89,994 publications) came from several countries, of which the top 15 (United States, United Kingdom, Germany, Canada, Italy, Japan, and China) accounts for 94.80% share of the global output during 2004-13. India’s global publication share was 1.52% and hold 14th rank in global publication output during 2004-13. The Indian prostate cancer output came from several organizations and authors, of which the top 20 and 19 contributed 41.81% and 24.05% share, respectively, during 2004-13. India’s international collaborative share in prostate cancer was 23.39%, which decreased from 24.42% to 22.98% from 2004-08 to 2009-13. Medicine accounted for the largest share (59.50%) of output in prostate cancer followed by biochemistry, genetics and molecular biology (40.13%), pharmacology, toxicology & pharmaceutics (27.63%), chemistry (8.55%), agricultural and biological sciences (4.31% share), and immunology and microbiology (2.70% share) during 2004-13. Diagnosis, screening, chemotherapy, radiotherapy, pathology and prognosis together account for 60.24% publications share among treatments methods used in Indian prostate cancer research during 2004-13. Only Delhi, Maharashtra, Uttar Pradesh and Tamil Nadu together contributed 57.82% share in Indian publications output in prostate cancer during 2004-13. The authors stressed the need for developing national policy for prostate cancer which should take care of screening for detection and diagnosis, management and treatment options of the prostate cancer patients in India.

Keywords: Prostate cancer; Publications; Scientometrics

Introduction

The prostate gland is part of a man’s reproductive and urinary systems. It is oval shaped with a rounded tip and its size varies (with age) from the size of a walnut to a small apple. The prostate surrounds the base (or neck) of the bladder. It has 2 lobes that surround the urethra. The urethra carries urine from the bladder, through the prostate, and out the penis. The prostate gland is covered in a layer of connective tissue called the prostatic capsule and is made up of different types of cells: (i) gland cells that produce the fluid portion of semen, (ii) muscle cells that control urine flow and ejaculation and (iii) fibrous cells that provide the supportive structure of the gland. Around the prostate, there are structures: (i) seminal vesicles - these glands produce semen and are found on both sides of the prostate, (ii) vas deferens – these tubes carry sperm from the testicles to the seminal vesicles, (iii) nerve bundles - these nerves control bladder and erectile function and are found on both sides of the prostate and (iv) muscles -these muscles control urination. The prostate gland is divided into three zones: (i) peripheral zone- it is the largest part of prostate and closest to the rectum. This zone accounts for approximately 75% the prostate tumors (approximately 75%); (ii) transition zone - a middle area of the prostate (about 20% of the prostate gland) and surrounds the urethra as it passes through the prostate; and (iii) central zone- The area in front of the transition zone of the prostate and is farthest from the rectum. The main function of the prostate is to produce the fluid portion of semen. A thin fluid (made continuously) rich in proteins and minerals that maintain and nourish sperm is produced by the gland cells within the prostate. When a man is sexually aroused, the prostate produces larger amounts of this fluid. It then mixes with sperm and is ejaculated as semen. However, its excess production passes from the body to the urine. The prostate also plays a part in controlling the flow of urine. The urethra runs from the bladder, through the prostate, and out through the penis. The muscle fibers of the prostate are wrapped around the urethra and are under involuntary...
nervous system control. These fibers contract to slow and stop the flow of urine.¹ Prostate cancer starts in the cells of the prostate several types of cells are found in the prostate, but almost all prostate cancers develop from the gland cells. Gland cells make the prostate fluid that is added to the semen. The cancer that starts in gland cells is called isadeno-carcinoma. Other rare types of cancer can also start in the prostate gland, including sarcomas, small cell carcinomas, and transitional cell carcinomas.²

Prostate cancer is the second most common cancer (with 15% of all cancer cases) in men, with an estimated 1.1 million cases (developed region -759,000 cases, developing regions -353,000, India-19,000) is diagnosed in 2012. The prostate cancer incidence varies across different geographical regions. It is very high in developed regions such as Australia/New Zealand and North America (Age Standardized Rates (ASR) 111.6 and 97.2 per 100,000 respectively). It is high in terms of Age Standarized Rates in few developed regions such as Caribbean (79.8), South Africa (61.8) and South America (60.1) and low in Asian region with estimated rates of 10.5 and 4.5 in Eastern and South Central Asia. With an estimated 307,000 deaths (developed regions-142,000, developing regions-165,000 and India-12,000) in 2012, prostate cancer is the fifth leading cause of death from cancer in men (6.6% of the total men deaths). Mortality rates in terms of Age Standarized Rates are observed generally high in predominantly black population (Caribbean, 20 per 100,000), Sub-Saharan Africa (ASRs 19-24 per 100,000), very low in Asia (2.9 per 100,000 in South Central Asia) and intermediate in the Americas and Oceania.³

In the past, there are no specific studies on the scientometric analysis of prostate cancer research both at global and national level. However, only few studies have been undertaken in the past on the contribution, citation impact, and evaluation of Indian cancer literature. Among such quantitative studies, Patra and Bhattacharya⁴ had analyzed World and Indian oncology research output during 1987-2003, using PubMed database. It studied research output and global contribution of different countries in world output. It mainly studied India’s cancer literature growth trends and explored the application of Bradford’s Law of Scattering for identifying core journals and Lotka’s Law for author productivity in Indian literature. It also identified the most active Indian institutions involved in cancer research. Lewison and Roe⁵ undertook a comprehensive study on Indian cancer research output during 1990-2010. It focused on Indian cancer literature, its growth, research impact, international collaborative publications share, publication output by geographical areas and, type of research, publication output by cancer site or manifestation and sources of funding for Indian research. The authors observed that distribution of Indian research by cancer site correlates positively with the relative disease burden. Basu, Roe and Lewison⁶ studied the Canada and USA settled (NRIs) Indian origin scholars in the field of cancer during three periods: 1988-90, 1998-2000 and 2008-10. Several authors have examined Indian research publications output in bone marrow research, oral cancer⁷ and cervical cancer⁸ and lymphoma cancer⁹. These publications have examined the literature growth, citation impact and global share, the contribution by sub-fields, type of research, cancer site, treatment methods and population age groups, contribution by type of Indian organization and geographical distribution, contribution and citation impact of top organizations and authors and pattern of communication. Keyan et al.¹⁰ examined the articles in 39 issues of Indian Journal of Cancer during 2003-12. It studied the literature growth, author productivity, authorship pattern, average length of articles and country collaboration of cancer research in India.

The main objectives of this study are to study the performance of Indian research in prostate cancer during 2004-13, based on publications output, as indexed in Scopus database. In particular, the study focuses on the following objectives to study:

- Growth of world and Indian research output by type of publication;
- Citation pattern of the Indian research output;
- Contribution, global publication share and citation impact of top 15 most productive countries;
- International collaboration share of publication of top 15 most productive countries and the extent of inter-country collaborative linkages among them and to identify the leading collaborative partners and their share in India’s output;
- Distribution of Indian research output by broad subject areas and study their growth and decline;
- Indian prostate cancer output by treatment methods and their distribution by geographical areas;
- Publication productivity and citation impact of most productive twenty Indian institutions and nineteen authors; and
- Leading media of communication

**Literature search**

The study retrieved and downloaded the publication data of the world and of 15 most productive countries in prostate cancer from the Scopus database (http://www.scopus.com) for 10 years during 2004-13. The keyword “prostate cancer” and “cancer or neoplasm or carcinoma” were used in “title, abstract and keyword” tag and restricting it to the period 2004-13 in “date range tag” was used for searching the global publication data and this become the main search string. When the main search string with restricted to 15 most productive countries in “country tag”, as shown below, the publication data on productive countries were obtained. When the main search string is further restricted to “subject area tag”, “country tag”, “source title tag”, “journal title name” and “affiliation tag”, we got information on distribution of publications by subject, collaborating countries, organiza-
tion-wise and journal-wise, etc. For citation data, the three years, two years, one year citation window was used for publications during 2004-11, 2012 and 2013. In addition, citations of publications were also collected from date of publications till the end of July 2014 for sections 4.1 and 4.10.

Literature search results

The world and India has published 89994 and 1368 publications in prostate cancer during 2004-13, which have increased from 6402 and 55 publications in 2004 to 11739 and 239 publications in 2014, registering an annual average growth rates of 7.87% and 18.77%. The cumulative growth of world and Indian publication output in prostate cancer research has increased from 37482 and 389 publications during 2004-08 to 52512 and 979 publications during 2009-13, witnessing a growth rate of 40.10% and 151.67%. India’s global publications share in prostate cancer was 1.52% during 2004-13, which increased from 1.04% during 2004-08 to 1.86% during 2009-13. The average citation per publication registered by Indian publications in prostate cancer was 5.23 during 2004-13, which had increased from 4.91 during 2004-08 to 5.35 during 2009-13. Of the total Indian publications in prostate cancer during 2004-13, articles constituted 67.03% share, reviews (21.35%), letters (3.07%), conference publications (2.70%), notes (2.12%), editorial (1.75%), book chapters (0.80%), short surveys (0.80%) and articles in press (0.07%) (Table 1).

 TABLE 1: World and Indian literature in prostate cancer: Growth, impact & international collaboration, 2004-13.

| Publication Years | World | India |
|-------------------|-------|-------|
|                   | TP    | TC    | ACPP | ICP  | %ICP |
| 2004              | 6402  | 55    | 246  | 4.47 | 10   | 18.18 |
| 2005              | 7013  | 59    | 192  | 3.25 | 10   | 16.95 |
| 2006              | 7350  | 77    | 341  | 4.43 | 18   | 23.38 |
| 2007              | 8144  | 85    | 471  | 5.54 | 19   | 22.35 |
| 2008              | 8573  | 113   | 661  | 5.85 | 38   | 33.63 |
| 2009              | 9234  | 127   | 459  | 3.61 | 27   | 21.26 |
| 2010              | 9830  | 147   | 778  | 5.29 | 30   | 20.41 |
| 2011              | 10390 | 227   | 1700 | 7.49 | 64   | 28.19 |
| 2012              | 11319 | 239   | 1935 | 8.10 | 56   | 23.43 |
| 2013              | 11739 | 239   | 365  | 1.53 | 48   | 20.08 |
| 2004-08           | 37482 | 389   | 1911 | 4.91 | 95   | 24.42 |
| 2009-13           | 52512 | 979   | 5237 | 5.35 | 225  | 22.98 |
| 2004-13           | 89994 | 1368  | 7148 | 5.23 | 320  | 23.39 |

TP = Total publications; TC = Total citations; ACPP = Average citations per publication; ICP = International collaborative publications

Citation pattern of research output

Citations of 1368 Indian publications during 2004-13 in prostate cancer were examined since the year of publication till June July 2014. During this period, 14428 citations were received by 1368 publications, leading to the average citation per publication of 10.55. Only 28.65% of the total publications did not get any citations (zero citation) and rest of the 71.35% publications were cited one or more times. Of the total cited publications, 3.29% publications (receiving more than 50 citations) contributed 34.27% citations share, 4.02% publications (received citations from 31 to 50) contributed 14.83% citations share, 17.91% publications (received citations from 11 to 30) contributed 33.28% citation share and the rest 46.13% publications (receiving citations from 1 to 20) contributed 17.63% citations share (Table 2).

 TABLE 2: Citations received by Indian publications in prostate cancer, 2004-13.

| No. of Citations | No. of Publications | Total Citations | % Publications | % Citations |
|------------------|---------------------|-----------------|----------------|-------------|
| 0                | 392                 | 0               | 28.65          | 0.00        |
| 1-10             | 631                 | 2543            | 46.13          | 17.63       |
| 11-30            | 245                 | 4802            | 17.91          | 33.28       |
| 31-50            | 55                  | 2139            | 4.02           | 14.83       |
| 51-100           | 32                  | 1959            | 2.34           | 13.58       |
| >100             | 13                  | 2985            | 0.95           | 20.69       |
| Total            | 1368                | 14428           | 100.00         | 100.00      |

* Citations are from date of publications till July 2014

Global publication share and citation impact of top 15 most productive countries

The total global research output in prostate cancer originated in 113 countries during 2004-13. Of the 113 countries, 87 countries produced 1 to 50 publications, 10 countries from 51 to 100 publications, 11 countries from 101 to 400 publications, 2 countries from 501 to 700 publications, 2 countries from 1401 to 1800 publications and 1 country between 4801 to 4900 publications during 2004-13.

Table 3 lists the output of top 15 most productive countries that produced 94.80% of the global output in prostate cancer during 2004-13. The publication share of 15 most productive countries in prostate cancer varied from 1.37% to 41.56%, with highest publication share (41.56%) coming from USA, followed by UK (7.19% share), Germany (6.64% share), Canada (5.44% share), Italy (5.08% share), Japan (5.03% share), China (4.51% share), France (4.28% share), Australia, Netherlands, Spain and Sweden (2.72% share), South Korea, India and Switzerland (from 1.37 to 1.97% share) during 2004-13. The global publication share has increased by 3.23% in China, followed by Italy (1.01%), South Korea (0.95%), India (0.83%), Australia (0.78%), Netherlands (0.49%), Canada (0.45%), Sweden (0.32%), France (0.30%), Switzerland (0.21%) and Spain (0.08%), as against decrease by 2.47% in USA, followed by Japan (1.05%), Germany (0.22%) and UK (0.12%) from 2004-08 to 2009-13. Similarly, the global publication rank has increased from 8th to 4th in case of China and Australia (from 11th to 9th), as against decrease in rank from 4th to 7th in case of Japan and France (from 7th to 8th) from 2004-08 to 2009-13. The publication rank of other countries has remained the same during this period.
TABLE 3: Publication output, global publication share and rank of top 15 most productive countries in prostate cancer, 2003-12.

| Country       | Number of Publications | Global Publication Share | Rank |
|---------------|------------------------|--------------------------|------|
|               | 2004-08 | 2009-13 | 2009-13 | 2004-08 | 2009-13 | 2009-13 | 2004-08 | 2009-13 | 2009-13 |
| United States | 16118   | 21287   | 37405   | 43.00   | 40.54   | 41.56   | 1       | 1       | 1       |
| United Kingdom| 2724    | 3751    | 6475    | 7.27    | 7.14    | 7.19    | 2       | 2       | 2       |
| Germany       | 2537    | 3441    | 5978    | 6.77    | 6.55    | 6.64    | 3       | 3       | 3       |
| Canada        | 1941    | 2958    | 4899    | 5.18    | 5.63    | 5.44    | 5       | 5       | 4       |
| Italy         | 1682    | 2888    | 4570    | 4.49    | 5.50    | 5.08    | 6       | 6       | 5       |
| Japan         | 2116    | 2412    | 4528    | 5.65    | 4.59    | 5.03    | 4       | 7       | 6       |
| China         | 985     | 3077    | 4062    | 2.63    | 5.86    | 4.51    | 8       | 4       | 7       |
| France        | 1538    | 2312    | 3850    | 4.10    | 4.40    | 4.28    | 7       | 8       | 8       |
| Australia     | 849     | 1600    | 2449    | 2.27    | 3.05    | 2.72    | 11      | 9       | 9       |
| Netherlands   | 909     | 1533    | 2442    | 2.43    | 2.92    | 2.71    | 10      | 10      | 10      |
| Spain         | 947     | 1367    | 2314    | 2.53    | 2.60    | 2.57    | 9       | 11      | 11      |
| Sweden        | 752     | 1221    | 1973    | 2.01    | 2.33    | 2.19    | 12      | 13      | 12      |
| South Korea   | 530     | 1241    | 1771    | 1.41    | 2.36    | 1.97    | 13      | 12      | 13      |
| India         | 389     | 979     | 1368    | 1.04    | 1.86    | 1.52    | 15      | 14      | 14      |
| Switzerland   | 467     | 762     | 1229    | 1.25    | 1.45    | 1.37    | 14      | 15      | 15      |
| World         | 37482   | 52512   | 89994   |         |         |         |         |         |         |

TABLE 4: International collaborative output, share and linkages of top 15 most productive countries during 2004-13.

| Country Name | TP | ICP | %CP | TCL* |
|--------------|----|-----|-----|------|
| United States (US) | 37405 | 8787 | 23.49 | 9715 |
| United Kingdom (UK) | 6475 | 2432 | 37.56 | 4066 |
| Germany (GER) | 5978 | 2424 | 40.55 | 3897 |
| Canada (CAN) | 4899 | 2313 | 47.21 | 3411 |
| Italy (ITL) | 4570 | 1802 | 39.43 | 3351 |
| Japan (JP) | 4528 | 963 | 21.27 | 1252 |
| China (CH) | 4062 | 1408 | 34.66 | 1577 |
| France (FR) | 3850 | 1487 | 38.62 | 2839 |
| Australia (AUS) | 2449 | 1024 | 41.81 | 1486 |
| Netherlands (NET) | 2442 | 1146 | 46.93 | 2312 |
| Spain (SPN) | 2314 | 808 | 34.92 | 1810 |
| Sweden (SWD) | 1973 | 1230 | 62.34 | 2285 |
| South Korea (SKOR) | 1771 | 444 | 25.07 | 542 |
| India (IND) | 1368 | 320 | 23.39 | 378 |
| Switzerland (SWT) | 1229 | 762 | 62.00 | 1245 |

*TP = Total publications; ICP=International collaborative publications; TCL = Total collaborative links with top 15 most productive countries
Sweden registered the highest share (62.34%) of international collaborative publications among the top 15 countries in prostate cancer during 2004-13, followed by Switzerland (60.00%), Canada (47.21%), Netherlands (46.93%), Australia (41.81%), Germany (40.55%), Italy (39.43%), France (38.62%), UK (37.56%), Spain (34.92%), China (34.66%), South Korea (25.70%), USA (23.49%), and India (23.39%) and Japan (21.27%). United States received the highest number (9715) of international collaboration linkages, followed by USA (4066 linkages), Germany (3897 linkages), Canada (3411 linkages), France (3351 linkages), Italy (332 linkages), Netherlands (2312 linkages), and Sweden (2285 linkages), China (1577 linkages), Australia (1486 linkages), Japan (1252 linkages), Switzerland (1245 linkages), South Korea (542 linkages) and India (378 linkages) during 2004-13 (Table 4).

The largest number of inter-country collaborative linkages (1457) was between USA-Canada, followed by USA-UK (1102 linkages), USA-China (1052 linkages), USA-Germany (1044 linkages), USA-Italy (923 linkages), USA-Sweden (668 linkages), USA-Japan (643 linkages), USA-France (616 linkages), USA-Netherlands (499 linkages), USA-Australia (470 linkages), UK-Germany (451 linkages), Germany-Italy (410 linkages), USA-Spain (407 linkages), UK-France (386 linkages), USA-South Korea (366 linkages), France-Italy (358 linkages), UK-Italy (356 linkages), Netherlands-UK (352 linkages), UK-Sweden (339 linkages), Germany-France (332 linkages), Germany-Netherlands (327 linkages), Canada-Germany (326 linkages), and so on, during 2004-13 (Table 4). From the above, we can conclude that China, Switzerland, South Korea and India have not been preferred partner for international collaboration among the top 15 countries.

### International collaboration

The share of international collaborative publications in India’s total publication output in prostate cancer research was 23.39% during 2004-13, which decreased from 24.42% during 2004-08 to 22.98% during 2009-13. India has collaborated with 72 countries in prostate cancer research during 2004-13 and the largest share (67.50%) was contributed by United States during 2004-13, followed by UK (9.06%), Germany (7.50%), Canada (7.19%), Japan and Saudi Arabia (5.00% each), Australia (4.38%), China (4.06%), France (3.75%) and Italy (3.44%) during 2004-13. The international collaborative publications share increased by 4.11% in Saudi Arabia, followed by China (2.78%), Canada (2.74%), France (2.33%), Australia (1.73%), UK (0.91%) and Germany (0.19), as against decrease by 8.79% in USA, followed by Italy (1.1%) and Japan (0.37%) from 2004-08 to 2009-13 (Table 5).

### Subject-wise distribution of research output

India’s prostate cancer research output during 2004-13 has been published in the context of six sub-fields (as reflected in Scopus database classification), with highest publications share (59.50%) coming from medicine, followed by biochemistry, genetics & molecular biology (40.13%), pharmacology, toxicology & pharmaceutics (27.63%), chemistry (8.55% share), agricultural & biological sciences (4.31% share) and immunology & microbiology (2.70% share).

The research activity, as reflected in activity index, has witnessed increase in, pharmacology, toxicology and pharmaceutics, chemistry, agricultural & biological sciences and immunology & microbiology in contrast to decrease in medicine and biochemistry, genetics & molecular biology from 2004-08 to 2009-13. Among these six subjects, the largest citation impact per publication (7.47) was registered by agricultural & biological sciences, biochemistry, genetics & molecular biology (6.71), chemistry (6.61), pharmacology, toxicology and pharmaceutics (6.34), medicine (4.83) and immunology & microbiology (3.89) during 2004-13 (Table 6).
TABLE 6: Subject-wise break-up of India’s publications in prostate cancer, 2003-13.

| S.N | Subject Areas | Number of Publications (TP)* | Activity Index | TC | ACPP | H-INDEX | ICP(%ICP) | % TP |
|-----|---------------|-----------------------------|---------------|----|------|---------|----------|------|
|     |               | 2004-08 | 2004-08 | 2004-08 | 2004-08 | 2004-13 | 2004-13 | 2004-13 | 2004-13 | 2004-13 |
| 1   | Medicine      | 259     | 555     | 814     | 111.90 | 95.27 | 3931     | 4.83 | 38   | 185 | (22.73%) | 59.50 |
| 2   | Biochemistry, Genetics & Molecular Biology | 166     | 383     | 549     | 106.33 | 97.48 | 3683     | 6.71 | 41   | 174 | (31.69%) | 40.13 |
| 3   | Pharmacology, Toxicology & Pharmaceutics | 66      | 312     | 378     | 61.40  | 115.34 | 2398     | 6.34 | 32   | 80  | (21.16%) | 27.63 |
| 4   | Chemistry     | 29      | 88      | 117     | 87.17  | 105.10 | 773      | 6.61 | 22   | 39  | (33.33%) | 8.55  |
| 5   | Agricultural & Biological Sciences | 14      | 45      | 59      | 83.45  | 106.58 | 441      | 7.47 | 16   | 24  | (40.68%) | 4.31  |
| 6   | Immunology & Microbiology | 5       | 32      | 37      | 47.52  | 120.85 | 144      | 3.89 | 9    | 10  | 27.03% | 2.70  |
|     | Total of the country | 389 | 979 | 1368 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 |

* There is a duplication of publications under various subject areas, as some journals covered are common in different subject areas.

TP=Total publications; TC=Total citations; ACPP=Average citations per publication; ICP=International collaborative publications.

### Table 7: Distribution of India’s prostate cancer publications by treatment methods, 2004-13.

| Treatment methods | Number of Publications | Share of Publications |  |
|------------------|------------------------|-----------------------|---|
|                  | 2004-08 | 2009-13 | 2004-08 | 2009-13 | 2004-08 | 2009-13 | 2004-08 | 2009-13 | 2004-08 | 2009-13 |
| Diagnosis        | 51     | 143     | 194     | 13.11  | 14.61  | 14.18  | 14.18  | 14.18  |
| Screening        | 32     | 131     | 163     | 8.23   | 13.38  | 11.92  | 11.92  | 11.92  |
| Chemotherapy     | 31     | 107     | 138     | 7.97   | 10.93  | 10.09  | 10.09  | 10.09  |
| Radiotherapy     | 29     | 87      | 116     | 7.46   | 8.89   | 8.48   | 8.48   | 8.48   |
| Pathology        | 40     | 69      | 109     | 10.28  | 7.05   | 7.97   | 7.97   | 7.97   |
| Prognosis        | 21     | 83      | 104     | 5.40   | 8.48   | 7.60   | 7.60   | 7.60   |
| Surgery          | 25     | 64      | 89      | 6.43   | 6.54   | 6.51   | 6.51   | 6.51   |
| Genetics         | 29     | 39      | 68      | 7.46   | 3.98   | 4.97   | 4.97   | 4.97   |
| Quality of Life  | 8      | 37      | 45      | 2.06   | 3.78   | 3.29   | 3.29   | 3.29   |
| Epidemiology     | 5      | 13      | 18      | 1.29   | 1.33   | 1.32   | 1.32   | 1.32   |
| Palliative care  | 4      | 4       | 8       | 1.03   | 0.41   | 0.58   | 0.58   | 0.58   |
| Total of the country | 389 | 979 | 1368 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 |

Prostate cancer publications by treatment methods

In terms of treatment methods used in prostate cancer during 2004-13, the largest publication share (14.18%) was registered by diagnosis, followed by screening (11.92%), chemotherapy (10.09%), radiotherapy (8.48%), pathology (7.97%), prognosis (7.60%), surgery (6.51%), genetics (4.97%), epidemiology (1.32%) and palliative care (0.58%) during 2004-13. The publication share has increased by 5.15% (from 8.23% to 13.38%) in screening, followed by 3.08% (from 5.40% to 8.48%) in prognosis, 2.96% (from 7.97% to 10.93%) in chemotherapy, 1.72% (from 2.06% to 3.78%) in quality of life, 1.50% (from 13.11% to 14.61%) in diagnosis, 1.43% (from 7.46% to 8.89%) in radiotherapy, 0.11% (from 6.43% to 6.54%) in surgery and 0.04% (from 1.29% to 1.33%) in epidemiology, as against decrease by 3.48% (from 7.46% to 3.98%) in genetics, 3.23% (from 10.28% to 7.05%) in pathology and 0.62% (from 1.03% to 0.41%) in palliative care from 2004-08 to 2009-13 (Table 7).

Geographical distribution of research output

Among Indian states and union territories contributing to prostate cancer research during 2004-13, the largest publication share (16.52%) comes from Delhi, followed by Maharashtra (15.35%), Uttar Pradesh (15.06%), Tamil Nadu (10.89%), Andhra Pradesh (7.38%), Karnataka (6.94%), Chandigarh (5.12%), West Bengal (4.61%), Punjab (2.41%), Haryana and Kerala (2.05% each), Madhya Pradesh (1.75%), Rajasthan (1.61%) and Pondicherry (0.51%).

Together the first four states account for 57.82% share of Indian publications in prostate cancer during 2004-13. The share of prostate cancer publications have increased by 4.21% (4.37% to 8.58%) in Andhra Pradesh, 1.53% (from 0.51% to 2.04%) in Rajasthan, 1.41% (from 3.60% to 5.01) in West Bengal, 1.08% (from 6.17% to 7.25%) in Karnataka, 0.85% (from 10.28% TO 11.13%) in Tamil Nadu and 0.35% (from 1.80% to 2.15%) in Kerala, as against decrease by 6.73% (from...
21.34% to 14.61%) in Delhi, 3.38% (from 17.48% to 14.01%) in Uttar Pradesh, 1.90% (16.71% to 14.81%) in Maharashtra, 1.09% (from 2.83% to 1.74%) in Haryana, 0.72% (from 1.03% to 0.31%) in Pondicherry, 0.43% (from 2.06% to 1.63%) in Madhya Pradesh, 0.39% (from 5.40% to 5.01%) in Chandigarh and 0.22% (from 2.57% to 2.35%) in Punjab from 2004-08 to 2009-13. (Table 8)

**TABLE 8:** Geographical distribution of prostate cancer research publications in India, 2004-13.

| Geographical Area | 2004-08 | 2009-13 | Share of Publications | 2004-08 | 2009-13 | 2004-08 | 2009-13 |
|-------------------|---------|---------|-----------------------|---------|---------|---------|---------|
| Delhi             | 83      | 143     | 21.34                 | 14.61   | 16.52   |
| Haryana          | 65      | 145     | 16.71                 | 14.81   | 15.35   |
| Uttar Pradesh    | 68      | 138     | 17.48                 | 14.10   | 15.06   |
| Tamil             | 40      | 109     | 10.28                 | 11.13   | 10.89   |
| Andhra Pradesh   | 17      | 84      | 4.37                  | 8.58    | 7.38    |
| Karnataka        | 24      | 71      | 6.17                  | 7.25    | 6.94    |
| Chandigarh        | 21      | 49      | 5.40                  | 5.01    | 5.12    |
| West Bengal      | 14      | 49      | 3.60                  | 5.01    | 4.61    |
| Punjab            | 10      | 23      | 2.57                  | 2.35    | 2.41    |
| Haryana          | 11      | 17      | 2.83                  | 1.74    | 2.05    |
| Kerala            | 7       | 21      | 1.80                  | 2.15    | 2.05    |
| Madhya Pradesh   | 8       | 16      | 2.06                  | 1.63    | 1.75    |
| Rajasthan         | 2       | 20      | 0.51                  | 2.04    | 1.61    |
| Pondicherry       | 4       | 3       | 1.03                  | 0.31    | 0.51    |

389 979 1368

Profile of top 20 most productive organizations

The productivity of 20 most productive Indian organizations in prostate cancer varied from 11 to 90 publications and together contributed 41.81% (572 publications) share in the cumulative publications output of India in prostate cancer research during 2004-13. The scientometric profile of these 20 Indian organizations is presented in Table 9. Seven organizations have registered higher publications output than the group average of 28.60: AIIMS-New Delhi (90 publications), SGPGIMS-Lucknow (59 publications), TMC-Mumbai (44 publications), PGIMER- Chandigarh (42 publications), IIM-Srinagar (39 publications), CSMUNIV- Lucknow (35 publications) and IICT-Hyderabad (34 publications). Six organizations have registered more than the average citation per publication (7.31) of 20 organizations: IITR-Lucknow (18.53), SGPGIMS-Lucknow (16.19), AIIMS-New Delhi (11.54), JNU-New Delhi (10.74), NIPER-Mohali (9.33) and CCMB-Hyderabad (8.45) during 2004-13.

Ten organizations have registered more than the average h-index (8.95) of all 20 organizations during 2004-13: AIIMS-New Delhi (17), SGPGIMS-Lucknow (14), JNU-New Delhi and University of Madras (13 each), IITR-Lucknow (12), JNU-New Delhi, IICT-Hyderabad and IIM-Srinagar (10 each), CDRI-Lucknow and TMH-Mumbai (9 each) during 2004-13. Eight organizations have achieved more than the average share of international collaborative publications (19.23%) of all 20 organizations: JNU-New Delhi (63.16%), AMU-Aligarh (46.15%), IISc-Bangalore (33.33%), GNDUNIV-Amrisar (30.77%), CDRI-Lucknow (29.41%), BARC-Mumbai (25.00%), IICT- Hyderabad (23.53%) and TMH-Mumbai (20.45%) during 2004-13.

The largest number of national collaborating linkages (15) among the most productive organizations were made by Panjab University (PUNJU), Chandigarh with five organizations (PGIMER-6, AIIMS-5, IIM-2, GNDUNIV-1 AND NIPER-1), followed by Postgraduate Institute of Medical Education & Research, Chandigarh with 14 linkages with 3 organizations (AIIMS-6, PUNJU-6 and NIPER-2), All India Institute of Medical Sciences, New Delhi with 13 linkages with 3 organizations (PGIMER-6, PUNJU-5 and NUNJ-2), CS Maharaj Medical University (CSMUNIV), Lucknow with 11 linkages with 2 organizations (CDRI-8 and SGPGIMS-5), Central Drug Research Institute, Lucknow with 8 linkages with 3 organizations (CSMUNIV-6, CCMB-1 and IITR-1), Indian Institute of Chemical Technology, Hyderabad with 8 linkages with 3 organizations (CSMUNIV-6, CCMB-1 and IITR-1), Sanjay Gandhi Postgraduate Institute pf Medical Education & Research, Lucknow with 7 linkages with 2 organizations (CSMUNIV-5 and CCMB-2), Tata Memorial Center, Mumbai with 7 linkages with 2 organizations (CSMUNIV-5 and CCMB-2), Guru Nanak Dev University, Amritsar with 6 linkages with 2 organizations (IIM-5 and PUNJU-1), Centre for Cellular & Molecular Biology, Hyderabad with 5 linkages with 3 organizations (IITC-2, SGPGIMS-2 and CDRI-1), National Institute of Pharmaceutical Education & Research, Mohali with 3 linkages with 2 organizations (PGIMER-2 and PUNJU-1) and Tata Memorial Centre, Mumbai, with 2 linkages with BARC, Mumbai.

Profile of top 19 most productive Indian authors

The top 19 most productive Indian authors have published 11 to 44 publications each and together contributed 24.05% (329 publications) share in the cumulative publications output of India in prostate cancer research during 2004-13. The scientometric profile of these 19 Indian authors is presented in Table 10.

Six authors have registered higher publications per author than the group average (17.32): Mittal RD (44 publications), Saxena AK (25 publications), Gupta NP (22 publications), Aruna Karan (22), Mandhani A (21) and Kumar R (6 publications). Eight authors have registered more than the average citation per publication (6.43) of all 19 authors during 2003-12: Mandal RK (18.60), Singh RP (13.58), Padhye S

© Gupta et al.

ISSN 2330-4049
(12.53), Mandal RK (9.00), Arunkumar A (7.33), Vijayababu MR (7.29), Aruna Karan (7.14) and Kamal A (6.92) during
2004-13. Eight authors have registered more than the average h-index (9.32) of all 19 authors during 2003-12: Mittal RD
and Aruna Karan with h-index of 14 each, followed by Vijayababu MR and Shukla y (12 each), Singh RP and
Arunkumar A (11 each), Mandhani A and Padhye S (10 each). Four authors have achieved more than the average share of
international collaborative publications (17.33%) of all 19 authors: Padhye S (100.00%), Singh RP (83.33%), Kamal
A (75.00%) and Hemal AK (75.0%).

### Media of communication

The 20 most productive journals contributed from 8 to 61 papers and together contributed 24.93% share (341 papers)
to the total journal publication output in prostate cancer during 2004-13. The publication share of these top 15 most
productive journals decreased from 27.25% to 24.00% from 2004-08 to 2009-13. Of these 20 journals, the highest citation
impact per paper of 45.89 by Cancer Research, followed by Molecular & Cellular Biochemistry (21.11), PLOS One
(20.35), BJU International (14.56), European Journal of Medicinal Chemistry (13.76), Bioorganic & Medicinal Chemistry
Letters (12.84), Urology (6.56), Asia Pacific Journal of Cancer Prevention (6.06), etc.

### TABLE 9: Scientometric profile of top 15 most productive Indian organizations in prostate cancer, 2004-13.

| S.N | Name of Organization                                           | TP  | TC   | ACPP | ICP | %ICP | HI  | NCL (NO) |
|-----|---------------------------------------------------------------|-----|------|------|-----|------|-----|----------|
| 1   | All India Institute of Medical Sciences, New Delhi.          | 90  | 1039 | 11.54| 16  | 17.78| 17  | 13(3)    |
| 2   | Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow. | 59  | 955  | 16.19| 4   | 6.78 | 14  | 7(2)     |
| 3   | Tata Memorial Hospital, Mumbai                                | 44  | 136  | 3.09 | 9   | 20.45| 9   | 2(1)     |
| 4   | Postgraduate Institute of Medical Education & Research, Chandigarh. | 42  | 77   | 1.83 | 7   | 16.67| 8   | 14(3)    |
| 5   | Indian Institute of Integrated Medicine, Srinagar.            | 39  | 183  | 4.69 | 5   | 12.82| 10  |          |
| 6   | CS Maharaj Medical University, Lucknow.                       | 35  | 89   | 2.54 | 5   | 14.29| 6   | 11(2)    |
| 7   | Indian Institute of Chemical Technology, Hyderabad.          | 34  | 165  | 4.85 | 8   | 23.53| 10  | 8(3)     |
| 8   | University of Madras.                                        | 27  | 160  | 5.93 | 4   | 14.81| 13  | 0        |
| 9   | Panjab University, Chandigarh.                                | 27  | 163  | 6.04 | 5   | 18.52| 10  | 15(5)    |
| 10  | Christian Medical College, Vellore.                          | 24  | 11   | 0.46 | 2   | 8.33 | 2   | 0        |
| 11  | Bhabha Atomic Research Center, Mumbai.                       | 20  | 88   | 4.40 | 5   | 25.00| 8   | 2(1)     |
| 12  | Jawaharlal Nehru University, New Delhi.                      | 19  | 204  | 10.74| 12  | 63.16| 13  | 2(1)     |
| 13  | Central Drugs Research Institute, Lucknow.                   | 17  | 110  | 6.47 | 5   | 29.41| 9   | 8(3)     |
| 14  | Indian Institute of Toxicological Research, Lucknow.         | 15  | 278  | 18.53| 2   | 13.33| 12  |          |
| 15  | National Institute of Pharmaceutical Education & Research, Mohali. | 15  | 140  | 9.33 | 2   | 13.33| 7   | 3(2)     |
| 16  | Indian Institute of Science, Bangalore.                      | 15  | 80   | 5.33 | 5   | 33.33| 5   |          |
| 17  | Guru Nanak Dev University, Amritsar.                         | 13  | 85   | 6.54 | 4   | 30.77| 7   | 6(2)     |
| 18  | Jawaharlal Nehru Technological University, Hyderabad.        | 13  | 33   | 2.54 | 2   | 15.38| 4   |          |
| 19  | Aligarh Muslim University, Aligarh.                          | 13  | 90   | 6.92 | 6   | 46.15| 7   |          |
| 20  | Centre for Cellular & Molecular Biology, Hyderabad.          | 11  | 93   | 8.45 | 2   | 18.18| 8   | 5(3)     |

| Total of 20 top organizations | 572 | 4179 | 7.31 | 110 | 19.23 | 8.95 |
| Total of the country           | 1368|       |      |     |       |      |

TP=Total publications; TC=Total citations; ACPP=Average citation per publication; ICP=International collaborative publications; HI=h-index; NCL=National collaborative linkages
In Summary, India has contributed 1368 publications in prostate cancer, which has increased from 55 to 239 publications from the year 2004 to 2013, registering an annual average growth rate of 18.77%. India’s publications in prostate cancer have registered citation impact per publication of 5.23 during 2004-13, which has increased from 4.91 during 2004-08 to 5.35 during 2009-13. India is ranked at 14th place in global research output, with global publications share of 1.52% during 2004-13, increasing from 1.04% during 2004-08 to 1.86% during 2009-13. India’s share of international collaborative publications in prostate cancer was 23.39% during 2004-13, which has decreased from 24.42% to 22.98% from 2004-08 to 2009-13. Only 71.35% of the total publications received 1 or more citations since their publications till June 2014. Of the total cited publications, 3.29% publications contributed 34.27% citations share, 4.02% publications contributed 14.83% citations share, 17.91% publications contributed 33.28% citation share and the rest 46.13% publications contributed 17.63% citations share during 2004-13. In terms of subject-wise contribution, the largest publication share (59.50%) comes from medicine, followed by biochemistry, genetics & molecular biology (40.13%), pharmacology, toxicology & pharmaceutics (27.63%), chemistry (8.55%), agricultural & biological sciences (4.31% share) and immunology & microbiology (2.70% share). The largest citation impact per publication (7.47) was made by agricultural & biological sciences, biochemistry, genetics & molecular biology (6.71), chemistry (6.61), pharmacology, toxicology and pharmaceutics (6.34), medicine (4.83) and immunology & microbiology (3.89) during 2004-13. In terms of treatment methods used in prostate cancer research, the largest publications share (14.18%) comes from diagnosis, followed by screening (11.92%), chemotherapy (10.09%), radiotherapy (8.48%), pathology (7.97%), prognosis (7.60%), surgery (6.51%), genetics (4.97%) during 2004-13. Delhi among Indian states & union territories, contributed the largest share (16.52%) to prostate cancer research, followed by Maharashtra (15.35%), Uttar Pradesh (15.06%), Tamil Nadu (10.89%), Andhra Pradesh (7.38%), Karnataka (6.94%), Chandigarh (5.12%), West Bengal (4.61%), etc during 2003-12. The 20 most productive Indian organizations contributing to prostate cancer research has contributed 572 publications, accounting for 41.81% share of the country’s publication output.

**TABLE 10**: Scientometric profile of top 19 Indian authors in prostate cancer, 2004-13.

| S.N | Name             | Affiliation                                                                 | TP  | TC  | ACPP | ICP | %ICP | HI  |
|-----|------------------|------------------------------------------------------------------------------|-----|-----|------|-----|------|-----|
| 1   | Mittal RD        | Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow           | 44  | 243 | 5.52 | 3   | 6.82 | 14  |
| 2   | Saxena AK        | Indian Institute of Integrated Medicine, Srinagar                            | 25  | 131 | 5.24 | 4   | 16.00| 9   |
| 3   | Gupta NP         | All India Institute of Medical Sciences, New Delhi                          | 22  | 92  | 4.18 | 2   | 9.09 | 9   |
| 4   | Karan A          | ALM Postgraduate Institute of Basic Medical Sciences, University of Madras, Madras | 22  | 157 | 7.14 | 3   | 13.64| 14  |
| 5   | Mandhani A       | Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow           | 21  | 73  | 3.48 | 2   | 9.52 | 10  |
| 6   | Kumar R          | All India Institute of Medical Sciences, New Delhi                          | 21  | 71  | 3.38 | 2   | 9.52 | 8   |
| 7   | Seth A           | All India Institute of Medical Sciences, New Delhi                          | 16  | 82  | 5.13 | 1   | 6.25 | 8   |
| 8   | Shukla Y         | Indian Institute of Toxicological Research, Lucknow                         | 15  | 279 | 18.60| 2   | 13.33| 12  |
| 9   | Mandal RK        | Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow           | 15  | 135 | 9.00 | 0   | 0.00 | 8   |
| 10  | Padhye S         | University of Pune                                                           | 15  | 188 | 12.53| 15  | 100.0| 10  |
| 11  | Vijayababu MR    | ALM Postgraduate Institute of Basic Medical Sciences, University of Madras, Madras | 14  | 102 | 7.29 | 2   | 14.29| 12  |
| 12  | Goel A           | CS Maharaj Medical University, Lucknow                                       | 14  | 22  | 1.57 | 0   | 0.00 | 4   |
| 13  | Jagannathan NR   | All India Institute of Medical Sciences, New Delhi                          | 14  | 57  | 4.07 | 2   | 14.29| 8   |
| 14  | Singh RP         | Jawaharlal Nehru University New Delhi                                        | 12  | 163 | 13.58| 10  | 83.33| 11  |
| 15  | Nayyar R         | All India Institute of Medical Sciences, New Delhi                          | 12  | 39  | 3.25 | 0   | 0.00 | 6   |
| 16  | Kamal A          | Indian Institute of Chemical Technology, Hyderabad                           | 12  | 83  | 6.92 | 3   | 25.00| 8   |
| 17  | Arunkumar A      | ALM Postgraduate Institute of Basic Medical Sciences, University of Madras, Madras | 12  | 88  | 7.33 | 2   | 16.67| 11  |
| 18  | Hemal AK         | All India Institute of Medical Sciences, New Delhi                          | 12  | 56  | 4.67 | 3   | 25.00| 8   |
| 19  | Thulkar S        | All India Institute of Medical Sciences, New Delhi                          | 11  | 56  | 5.09 | 1   | 9.09 | 7   |
|     | **Total output of India** | 1368                                                                 |     |     |      |     |      |     |

**Share of 19 authors in India’s output**: 24.05

TP=Total publications; TC=Total citations; ACPP=Average citation per publication; ICP=International collaborative publications; HI=h-index
The average productivity, average citation impact per publication, h-index and share of international collaborative publications of the 15 most productive Indian organizations were 26.80, 7.31, 8.95 and 19.23% during 2004-13. The 19 most productive Indian authors contributing to prostate cancer research has contributed 329 publications, accounting for 24.05% share of the country’s publication output. The average productivity, average citation impact per publication, h-index and share of international collaborative publications of the 15 most productive Indian authors were 17.32, 6.43, 9.32 and 17.33% during 2003-12.

### Conclusion

In order to increase the national output and international collaboration and improve citation impact, there is an urgent need to increase awareness and understanding of the burden of disease associated with prostate cancer, undertake the evaluation of existed prostate cancer related programs and establish a national prostate cancer program at the national level in India. It is also important to develop a systematic screening program for detection and diagnosis of prostate cancer cases to be followed by evolution of suitable management strategy and more effective treatment options for treatment of prostate cancer. There is also need to increase funding support for research and development (R&D) and develop training programs for concerned persons at different levels.

### References

1. Canadian Cancer Society. Prostate cancer. Anatomy and physiology of the prostate. 2014. Available from [http://www.cancer.ca/en/cancer-information/cancertype/prostate/anatomy-and-physiology/?region=on](http://www.cancer.ca/en/cancer-information/cancertype/prostate/anatomy-and-physiology/?region=on).
2. American Cancer Society. What is prostate cancer? 2014. Available from [http://www.cancer.org/cancer/prostatecancer/detailedguide/prostate-cancer-what-is-prostate-cancer](http://www.cancer.org/cancer/prostatecancer/detailedguide/prostate-cancer-what-is-prostate-cancer).
3. WHO & International Agency for Research on Cancer. GLOBOCAN 2012: Estimated cancer incidence, mortality and prevalence worldwide in 2012. Cancer Fact Sheet. Prostate Cancer. IARC 2014. Available from [http://globocan.iarc.fr/Pages/factsheets_cancer.aspx](http://globocan.iarc.fr/Pages/factsheets_cancer.aspx).
4. Patra SK, Bhattacharya P. Bibliometric study of cancer research in India. DESIDOC Bulletin of Information Technology 2005; 25:11-8.
5. Lewison G, Roe P. The evaluation of Indian cancer research, 1990-2010. *Scientometrics* 2012; 93: 167-81.

### Conflict of interest

The authors declare that they have no conflicts of interest. The authors alone are responsible for the content and writing of the paper.
6. Basu A, Roe P, Lewis G. The Indian diaspora in cancer research: A bibliometric assessment for Canada and the USA. 2014, Available from http://sticonference.org/Proceedings/vol1/Basu_Indian_110.pdf
7. Gupta BM, Bala A. Bone marrow research in India: A scientometric study, 2003-12. *Journal of Bone Marrow Research* 2013; 1: 108.
8. Gupta R, Gupta BM, Ahmed M, Tiwari R. Oral cancer research: A scientometric assessment of Indian publications output during 2003-12. *Onc Gas Hep Rep* 2014; 3: 14-22.
9. Gupta R, Gupta BM, Ahmed M, Tiwari R. Cervical cancer in India: A scientometric study of publications, 2003-12. *Oncology, Onc Gas Hep Rep* 2014; 3: 4-13.
10. Gupta R, Gupta, BM. Indian lymphoma research: A scientometric analysis of Indian research output during 2004-13. *COLNET Journal of Scientometrics & Information Management* 2014; 8: 419-436.
11. Santhanakarthikeyan S, Grace M, Jeyshankar R. Research publications to Indian Journal of Cancer: a scientometric analysis. *Library Hi Tech News* 2014; 31: 21-5.